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Abstract
Heterozygous mutation of the transcription factor HNF1B is the most common cause of monogenetic
developmental renal disease. Disease-associated mutations fall into two categories: HNF1B intragenic mutations and
a 1.3 Mb deletion at chromosome 17q12. An increase in neurodevelopmental disorders has been observed in
individuals harbouring the 17q12 deletion but not in patients with HNF1B coding mutations.
Previous investigations have concentrated on identifying a genetic cause for the increase in behavioural problems
seen in 17q12 deletion carriers. We have taken the alternative approach of investigating the DNA methylation
profile of these two HNF1B genotype groups along with controls matched for age, gender and diabetes status
using the Illumina 450K DNA methylation array (total sample n = 60).
We identified a number of differentially methylated probes (DMPs) that were associated with HNF1B-associated
disease and passed our stringent experiment-wide significance threshold. These associations were largely driven by
the deletion patients and the majority of the significant probes mapped to the 17q12 deletion locus. The observed
changes in DNA methylation at this locus were not randomly dispersed and occurred in clusters, suggesting a
regulatory mechanism reacting to haploinsufficiency across the entire deleted region.
Along with these deletion-specific changes in DNA methylation, we also identified a shared DNA methylation
signature in both mutation and deletion patient groups indicating that haploinsufficiency of HNF1B impacts on the
methylome of a number of genes, giving further insight to the role of HNF1B.
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Introduction
The most common monogenic cause of developmental
kidney disease is heterozygous mutation of the hepato-
cyte nuclear factor 1β (HNF1B) gene, located at chromo-
some 17q12 [1–3]. This gene encodes a transcription
factor with important roles in the development of the
kidney, pancreas, genital tract and liver [4]. Renal cysts
are the most frequently observed clinical feature in
HNF1B-associated renal disease, although the phenotype
is very variable despite the single genetic aetiology [5].
Abnormalities are often detected on prenatal ultrasonog-
raphy, where bilateral hyperechogenic kidneys with
normal or slightly increased size are commonly found
[6]. The prevalence of HNF1B-associated renal disease
depends on which study cohort is selected; the detection
rate ranges from 5% in children ≤ 16 years with renal
aplasia/hypoplasia and chronic kidney disease to 31% in
children with renal cysts, hyperechogenicity, hypoplasia
or a single kidney [2, 7].
Extra-renal phenotypes are also common and include
early-onset diabetes mellitus, pancreatic hypoplasia,
genital tract malformations and abnormal liver function
tests [8–13]. The mean age at diagnosis of diabetes is
24 years but can vary from the neonatal period to late
middle age [14]. The pathophysiology reflects a combin-
ation of β cell dysfunction and insulin resistance; dys-
function of β cells results in reduced insulin secretion
and is likely to be a consequence of pancreatic
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hypoplasia [10]. Most patients require treatment with in-
sulin [14].
Heterozygous mutations in HNF1B generally occur in
two forms; approximately 50% of patients are affected by
an intragenic mutation (base substitution or small
insertion/deletion within the HNF1B gene) with the
other common mutation being a ~ 1.3 Mb deletion at
chromosome 17q12, which encompasses the entire
HNF1B gene [15, 16]. This region of chromosome 17 is
susceptible to genomic rearrangement, which is
mediated by non-allelic homologous recombination be-
tween flanking segmental duplications [17]. Interestingly,
the recurrent 17q12 deletion has also been associated
with neurodevelopmental disorders, such as autism
spectrum disorder and attention-deficit hyperactivity
disorder [18, 19]. The 1.3 Mb deleted region contains 14
genes in addition to HNF1B, and it is not currently clear
what genetic mechanism gives rise to this neurodevelop-
mental comorbidity. Until recently, there was no evidence
to suggest a genotype-phenotype correlation for any of the
other clinical features seen in HNF1B-associated disease;
this is consistent with haploinsufficiency as the underlying
disease mechanism [15, 16]. However, recent work by
Dubois-Laforgue and colleagues has shown renal function
may be worse in patients with an HNF1B intragenic muta-
tion than in those with a deletion [20].
Expression of the phenotype can vary significantly be-
tween families carrying the same HNF1B mutation and
even between affected members of the same family,
which suggests that additional genetic and/or environ-
mental modifiers might influence the HNF1B pheno-
type. Most efforts to understand this phenotypic
variation have concentrated on studying changes in the
DNA sequence. To date, epigenetic mechanisms which
act to developmentally regulate gene expression via
modifications to DNA, histone proteins and chromatin
have not been explored. DNA methylation is the most
well characterised and stable epigenetic modification,
influencing gene expression via the disruption of tran-
scription factor binding and the attraction of
methyl-binding proteins that initiate chromatin com-
paction and gene silencing. DNA methylation can be
directly affected by DNA sequence variation—including
large structural variants—both locally (in cis) and at
more distal locations in the genome (in trans) [21–24].
In this study, we set out to characterise the epigenetic
signature of HNF1B-associated disease and to deter-
mine if the signature differs depending on mutation
classification: we profiled genome-wide patterns of
DNA methylation in 20 individuals with an HNF1B in-
tragenic mutation (HNF1Bmtn), 20 individuals with a
17q12 deletion encompassing HNF1B (17q12del) and
20 controls (ctrl) matched for age, gender and diabetes
status.
Methods
Sample description
DNA was isolated from whole blood collected from unre-
lated individuals with HNF1B-associated disease who had
been referred for genetic testing to Exeter Molecular Gen-
etics Laboratory from 1998 to 2012; the criterion for initial
referral was suspicion of HNF1B-associated disease by the
referring clinician. DNA was isolated using standard phe-
nol:chloroform methods and checked for quality and pur-
ity. Informed consent was obtained to perform HNF1B
genetic testing as part of their clinical care, and the study
was conducted in agreement with the Declaration of
Helsinki Principles. Mutation screening was performed by
sequencing of coding exons and exon-intron boundaries
together with gene dosage assessment by multiplex
ligation-dependent probe amplification (MLPA) as previ-
ously described [16, 25]. Control DNA was collected from
two sources: (i) for individuals without diabetes mellitus,
controls were individuals referred to Exeter Molecular
Genetics Laboratory as above but with no HNF1B gene
mutation or deletion detected on genetic testing; (ii) for
individuals with diabetes mellitus, controls were individ-
uals from the UNITED (Using pharmacogeNetics to Im-
prove Treatment in Early-onset Diabetes) study with
presumed type 1 diabetes mellitus based on a urine
C-peptide/creatinine ratio ≥ 0.2 nmol/mmol with positive
islet autoantibodies [26]. All individuals had a serum cre-
atinine level < 250 μmol/L and were matched for age, sex
and presence of diabetes (Table 1). All samples included
in the study were unrelated. Two patients in the 17q12
deletion group had known neurodevelopmental disease (a
10-year-old female with developmental delay and a
31-year-old male with Asperger’s syndrome).
Methylomic profiling
Blood-derived DNA was profiled using the HumanMethy-
lation450 BeadChip (Illumina, San Diego, CA, USA) and
scanned on an Illumina HiScan System (Illumina, San
Diego, CA, USA). Illumina Genome Studio software was
used to extract the raw signal intensities of each probe
(without background correction or normalisation). Signal
intensities for each probe were imported into R [27] using
the methylumi and minfi packages [28, 29]. Multidimen-
sional scaling plots of sex chromosome probes were used
to check that the predicted sex corresponded with the re-
ported sex for each individual. The 65 SNP probes,
cross-hybridising probes [30, 31] and probes containing a
SNP 10 bp from the extension position (MAF > 0.05) were
excluded from analysis [30]. The ‘pfilter’ function of the
wateRmelon package [32] was used to filter data by bead-
count and detection P value. Samples with > 1% probes
with a detection Pvalue > 0.01 were removed, along with
probes with a detection P value > 0.05 in at least 1% of
samples and/or a beadcount < 3 in 5% of samples were
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also removed. The ‘dasen’ function in wateRmelon was
used to normalise the data as previously described [32].
The number of samples that passed quality control was
60 (HNF1B intragenic mutation (n = 20), 17q12 deletion
(n = 20) and control (n = 20) and a total of 388,295 CpG
sites were included in the final dataset.
Bisulfite pyrosequencing
A selected region was chosen to verify the array findings
using the complementary technology of bisulfite pyrose-
quencing using the Qiagen Q24 Pyrosequencer (Qiagen,
Hilden, Germany) (see [33]). Primers, probes and the
PCR conditions for the selected region can be found in
Additional file 1: Table S1; the sequencing reaction was
performed using the manufacturer’s protocol.
Statistical analysis
Differentially methylated position (DMP)
The one-way analysis of variance (ANOVA) test was
used to test for differentially methylated sites associated
with one of the three groups: HNF1B intragenic muta-
tion (n = 20), 17q12 deletion (n = 20) or control (n = 20).
DNA methylation values for each probe were regressed
against HNF1B status with covariates for age, gender,
diabetes status and cellular composition. As cell count
data were not available for these DNA samples these
were estimated from the DNA methylation data using
both the Epigenetic Clock software [34] and the
Houseman algorithm [35, 36]. To determine which
group was driving the association behind the significant
ANOVA results, the T statistics for controls versus each
of the two HNF1B distinct genetic groups were extracted
from the regression model. The presence of the 17q12
deletion was confirmed by analysing the DNA methyla-
tion raw data using the function ‘champ.CNA’ from the
package ChAMP [37].
Differentially methylated regions (DMRs)
The P values for the comparisons between the control
group and HNF1B genotype status from the regression
analysis were converted into BED files and run through
the comb-p [38] pipeline with a seed of (5 × 10−4) and dis-
tance parameter set to 500 bp. Briefly, comb-p generates
DMRs by (1) calculating the auto-correlation between
probes to adjust the input DMP P values using the
Stouffer-Liptak-Kechris correction, (2) running a peak
finding algorithm over these adjusted P values to identify
enriched regions around a seed signal, 3) calculating re-
gion P value using the Stouffer-Liptak correction and (4)
correcting for multiple testing with the one-step Šidák
correction. Significant regions were identified as those
with at least two probes and corrected P value < 0.05.
Results
All samples characterised as 17q12 deletion carriers were
confirmed by the CNV calling function in CHAMP which
uses the intensity data from the DNA methylation array
(see Additional file 2: Figure S1). The probe-wise ANOVA
analysis on the three groups (HNF1B intragenic mutation,
17q12 deletion and control) identified 21 differentially
methylated positions (DMPs) (see Table 2) that passed our
experiment-wide significance threshold (P < 1 × 10−7),
representing a 5% family-wise error-rate estimated from
5000 permutations (see [39]), with 94 additional DMPs
reaching a more relaxed ‘discovery’ threshold of P < 5 ×
10−5 (Additional file 3: Table S2). To determine which
group was driving this association, we extracted the P
values for the T statistics from the model HNF1B intra-
genic mutation vs control and 17q12 deletion vs control;
these results clearly show that the 17q12 deletion group is
driving most of the associations seen in the ANOVA (see
Table 2). All of the significant DMPs (P < 1 × 10−7) are
located in the 17q12 deletion region (see Figs. 1 and 2)
suggesting that the deletion is exerting effects in cis.
Table 1 Sample demographic table
HNF1B intragenic mutation
(n = 21)
17q12 deletion
(n = 21)
Control*
(n = 21)
Median age, years (interquartile range) 10 (2–28) 9 (2–31) 9 (2–29)
Sex, n (%) Male 8 (38) Male 8 (38) Male 8 (38)
Diabetes, n (%) 9 (43) 9 (43) 9 (43)
Renal abnormality, n (%)
-Renal cysts/cystic dysplasia 12 (57) 12 (57) 8 (38)
-Renal hyperechogenicity 2 (10) 1 (5) 2 (10)
-Single kidney 1 (5) 1 (5) 1 (5)
-Multicystic and dysplastic kidney 2 (10) 2 (10) 1 (5)
-Obstruction – 2 (10) –
The samples were matched for age, sex and diabetes status; all individuals had a serum creatinine level < 250 μmol/L
*For individuals without diabetes mellitus, controls were individuals with no HNF1B gene mutation or deletion detected on genetic testing; for individuals with diabetes
mellitus, controls were individuals from the UNITED (Using pharmacogeNetics to Improve Treatment in Early-onset Diabetes) study with presumed type 1 diabetes
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While this region appears to be driving the main asso-
ciations observed, probes situated outside the deletion
region, which are associated with both HNF1B geno-
type groups, are strongly correlated (r = 0.63, P = 2.626E
−07); see Fig. 3 and Additional file 4: Table S3 for a list
of probes that are significantly differently methylated in
both HNF1B genotype groups compared to controls.
DMR analysis comparing controls with the 17q12
deletion group identified a number of regions that were
significant after correction for multiple comparisons using
the comb-p program (Table 3). The majority of the DMRs
identified were located in the 17q12 deletion region (Fig. 2).
However, there were a few regions outside the deletion
region that exhibited significant differential methylation;
of interest were changes in the gene SLC1A3 (corrected
P = 4.71E−07, mean DNA methylation beta value Δ − 0.06),
which has previously been implicated in Autism [40]. The
DMR located in intron 3 of this gene was selected for
verification with pyrosequencing. The assay designed only
covered two of the three original probes comprising the
DMR but did include an additional five CpG sites that were
not present on the 450K array. The pyrosequencing data
was converted into beta values (by dividing the pyrose-
quencing % values by 100) and regressed against HNF1B
status with covariates for age, diabetes status, gender
and cell composition as in the initial analysis. The
five additional sites assayed by the pyrosequencer all
showed significant hypomethylation (P < 0.01) in the 17q12
deletion patients compared to the controls (see Fig. 4).
In contrast, only one significant DMR was located in
the analysis comparing controls with the HNF1B muta-
tion group (see Table 3).
Discussion
In this study, we have assessed genome-wide patterns of
DNA methylation in DNA derived from the blood of in-
dividuals with HNF1B-associated disease along with
matched healthy controls. The aim of this experiment
was to determine if there was an epigenetic signature
that can distinguish HNF1B intragenic mutation patients
from those with a 17q12 deletion. While both genotype
groups result in developmental kidney disease only
individuals with the 17q12 deletion appear to have a
greater risk of developing neuropsychiatric symptoms,
Table 2 Top results from the probe-wise ANOVA analysis. The T statistic results from the regression analysis indicate that the
association is mainly driven by the 17q12 deletion patients. DMP results are annotated with their genomic location and gene
annotation taken from the annotation files provided by Illumina. (*The coefficient value is equivalent to the magnitude of change in
DNA methylation beta value and the direction of effect is in comparison to the control group)
Illumina
Probe ID
F statistic ANOVA
P value
ANOVA
q values
CHR MAPINFO
(hg19)
Gene name ctrl v 17q12del ctrl vs HNF1B mtn
T statistic Coefficient* P value T statistic Coefficient* P value
cg06475972 47.017 4.00E-12 1.55E−06 17 34842357 ZNHIT3 9.045 0.043 5.06E−12 0.074 0.000 0.942
cg17953633 43.696 1.28E−11 2.49E−06 17 34957751 MRM1 8.532 0.069 2.97E−11 −0.417 − 0.003 0.678
cg24685795 40.277 4.52E−11 5.84E−06 17 34851276 ZNHIT3 − 8.075 − 0.107 1.47E−10 0.674 0.008 0.504
cg18269801 37.212 1.48E−10 1.44E−05 17 35732756 ACACA − 8.088 − 0.061 1.40E−10 − 0.184 − 0.001 0.855
cg05527869 35.891 2.52E−10 1.95E−05 17 35294476 LHX1 7.988 0.025 1.99E−10 0.310 0.001 0.758
cg04264908 35.376 3.10E−10 2.01E−05 17 35303330 8.057 0.060 1.56E−10 0.716 0.005 0.477
cg22359664 32.781 9.19E−10 5.10E−05 17 35289432 7.094 0.044 4.75E−09 − 1.023 − 0.006 0.311
cg07037057 30.723 2.25E−09 0.000107005 17 35969138 SYNRG 7.684 0.076 5.84E−10 1.382 0.012 0.173
cg18103097 30.332 2.68E−09 0.000107005 17 35414317 − 7.386 − 0.071 1.68E−09 − 0.415 − 0.004 0.680
cg20151045 30.270 2.76E−09 0.000107005 17 35414114 AATF − 7.242 − 0.051 2.80E−09 − 0.018 0.000 0.986
cg20951949 29.512 3.88E−09 0.000136867 17 34898162 − 7.047 − 0.078 5.60E−09 0.254 0.003 0.801
ch.17.958355F 28.600 5.89E−09 0.000190431 17 35991457 DDX52 7.365 0.055 1.81E−09 1.110 0.008 0.273
cg19678067 27.750 8.74E−09 0.00026103 17 34901173 GGNBP2 6.725 0.033 1.77E−08 − 0.509 − 0.002 0.613
cg06655187 27.194 1.14E−08 0.000315011 17 34842929 ZNHIT3 7.335 0.018 2.01E−09 1.984 0.004 0.053
cg03146993 26.915 1.30E−08 0.000335768 17 35297146 LHX1 6.987 0.041 6.95E−09 0.487 0.003 0.628
cg18574725 26.761 1.40E−08 0.000338748 17 34900600 GGNBP2 6.659 0.032 2.24E−08 − 0.370 − 0.002 0.713
cg06397845 26.545 1.55E−08 0.000353603 17 35732737 ACACA − 6.809 − 0.066 1.31E−08 − 0.092 − 0.001 0.927
cg00356511 26.177 1.85E−08 0.000398715 17 35716273 ACACA 6.279 0.024 8.68E−08 − 1.035 − 0.004 0.306
cg02787306 25.017 3.26E−08 0.000665877 17 34957963 MRM1 6.652 0.044 2.29E−08 0.209 0.001 0.835
cg27614319 24.275 4.72E−08 0.000916069 17 35079061 6.453 0.040 4.68E−08 − 0.073 0.000 0.942
cg04993975 24.159 5.00E−08 0.000924571 17 35294472 LHX1 6.648 0.024 2.33E−08 0.555 0.002 0.582
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suggesting the contribution of other genes or regulatory
mechanisms are at play.
We first examined site-specific genome-wide patterns
of DNA methylation in the three groups studied
(HNF1B mutations, 17q12 deletion and controls) and
found striking changes in DNA methylation of the
17q12 deletion region. The 21 DMPs that reached our
experimental-wide significance threshold all mapped to
the 17q12 deletion region. While we do see a drop in
signal intensity in this region in the deletion samples, it
is consistent across the methylated and unmethylated
channels so will not influence the calculated beta values.
Interestingly, the direction of effect is not consistent,
with probes exhibiting both gains and losses of DNA
methylation suggesting the observed changes are not a
technical artefact on the array resulting from the
haploinsufficiency of the region. Comparing the two
HNF1B genotype groups with controls separately con-
firmed that the association located to the 1.3 Mb dele-
tion at chromosome 17q12 was driven by the 17q12
deletion samples.
Given that DNA methylation at adjacent probes is
often correlated, we employed regional-based analysis
and identified 20 DMRs in the 17q12 deletion sam-
ples, 13 of which were located in the 1.3 Mb deletion
region. The most significant DMR mapped upstream
of the gene LHX1 (corrected P = 3.37E−18, mean
DNA methylation beta Δ + 0.02) (see Additional file 5:
Figure S2), which is known to play a role in brain de-
velopment and function [41, 42] as well as being dir-
ectly regulated by HNF1B during kidney development
[43, 44].
Fig. 1 Manhattan plots of the three analyses. a P values from the ANOVA test on the three genotype groups (HNF1B intergenic mutation, 17q12
deletion and controls). Highlighted in green are the 450K probes that are located in the 17q12 deletion region. b P values from the T statistic
from the regression model on controls compared to the 17q12 deletion samples. c P values from the T statistic from the regression model on
controls compared to the HNF1B mutation samples. (The red line indicates experiment-wide significance threshold (P < 1 × 10−7), and the blue
line is a more relaxed ‘discovery’ threshold of P < 5 × 10–5)
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These observations suggest a possible compensatory
mechanism mediated by DNA methylation reacting to
haploinsufficiency in the vicinity of the deletion. The
enrichment of DMRs in this region indicates that this
phenomenon is not entirely random and highlights a
number of loci in the region that may have regulatory
importance. Recently, DNA methylation has been
found to have a major role in “fine-tuning” the ex-
pression of genes located in CNVs found in various
different cancers [45].
While there is a substantial enrichment of DMRs in
the deletion region a number of DMRs were identified
elsewhere in the genome, one of which was located in
the gene SLC1A3 on chromosome 5. Genetic variations
in this gene have been linked to autism and expression
changes in this gene have been identified in schizophre-
nia patients; both these disorders have been associated
with the 17q12 deletion [18, 46]. Further work is needed
to identify whether alterations in the DNA methylation
profile in this gene affect gene function.
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Fig. 2 This figure illustrates the 17q12 deletion locus with the identified DMRs highlighted across the region. The regression coefficient and
P values from the analysis comparing the 17q12 deletion subject with controls illustrates that both hyper and hypo DNA methylation changes
are associated with the deletion
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So far, we have concentrated on the differences in the
DNA methylation signature in the 17q12 deletion
subjects which are not shared by the HNF1B mutation
subjects. However, these two groups have similar
phenotypes and this was reflected in the DNA
methylation profile of the two groups once the probes
located in the 17q12 region are removed, indicating that
there is a shared network of genes that are dysregulated
due to the haploinsufficency of HNF1B (see Fig. 3 and
Additional file 4: Table S3). The majority of these shared
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Fig. 3 This scatterplot demonstrates the concordance in effect size between the two HNF1B genetic groups compared to controls when probes
in the 17q12 deletion region (coloured green) are discounted
Table 3 Differential methylation regional (DMR) analysis on the two HNF1B deficient groups of patients compared to the controls
(highlighted in blue is the DMR residing in the gene SLC1A3 which was validated using pyrosequencing)
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probes are significantly hypomethylated in both patient
groups compared to controls and include cg01445838
(17q12del vs control P = 5.38E−05, coefficient = − 0.064,
HNF1B mutation vs control P = 0.000213, coefficient = −
0.052), which is located in the maternally imprinted gene
PLAGL1. This gene is known to be involved in fetal
growth and is necessary for normal pancreatic islet de-
velopment [47]. Furthermore, loss of DNA methylation
at this locus results in transient neonatal diabetes melli-
tus which is postulated to be caused by an increase in
expression of PLAGL1 [48].
The main limitation of this study is that it uses
blood-derived DNA and not disease-relevant tissue and/
or cells (e.g. the kidney or the brain). However,
genetic-mediated changes in DNA methylation (methy-
lation QTLS) have been found to be considerably stable
across different tissues and cell types [39] suggesting
that we may be able to extrapolate these findings to
other more relevant tissues.
Clinical details were taken from information available
at the time of referral for genetic testing; there may be
patient factors present, including medication history,
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Fig. 4 This figure shows the validation of the DMR located in the gene SLC1A3 with bisulfite pyrosequencing. All CpGs assayed, including those
not present on the 450K array, show significant hypomethylation in subjects harbouring a 17q12 deletion
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which we have been unable to control for and may have
influenced our results. Further, we also do not have de-
tailed psychiatric data available for the samples included
in this study so we cannot make any assumptions re-
garding the DNA methylation status of the 17q12 dele-
tion and the increased prevalence of psychiatric
symptoms. Many of the individuals were too young to
be assessed for schooling difficulties and the features of
neurodevelopmental disease often do not become appar-
ent until children are older.
Conclusion
We have identified significant DNA methylation alter-
ations in individuals with a 17q12 heterozygous deletion,
which localise to a 1.3 Mb deletion region. The observed
changes in DNA methylation at this locus are not ran-
domly dispersed and occur in clusters suggesting a regu-
latory mechanism reacting to haploinsufficiency across
the deleted region. Along with these deletion-specific
changes in DNA methylation, we also identified a com-
mon DNA methylation signature in both genotype
groups, indicating that haploinsufficiency of HNF1B im-
pacts on the methylome of a number of genes. Further
work should investigate the role of these genes in the
manifestation of the various phenotypes associated with
deficiency of HNF1B and investigate gene expression
changes associated with DNA methylation status across
the deletion region in disease relevant tissues. Also the
increased prevalence of psychiatric symptoms in patients
with the 17q12 deletion should be considered and
whether alterations in DNA methylation in this region
differ depending on psychiatric diagnosis.
Due to the rare nature of HNF1B mutations/deletions,
validation of these findings in an independent popula-
tion was not possible in this study but further work
should investigate DNA methylation changes in cis of
other more common disease associated copy number
variations.
To conclude, we have identified several genes that are
differentially methylated in HNF1B-associated disease,
some of which are specific to 17q12 deletion subjects.
Further, this study is, as far as we are aware, the first to
document organised changes in DNA methylation across
a large deletion region suggestive of a compensational
role of this epigenetic modification.
Additional files
Additional file 1: Table S1. SLC1A3 bisulfite pyrosequencing assay
conditions. (XLSX 11 kb)
Additional file 2: Figure S1. This figure illustrates the extent of the
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